neuropathic%20pain
NEUROPATHIC PAIN
Neuropathic pain is the sensation of pain due to abnormal discharges of impaired or injured neural structures in the peripheral &/or central nervous system.
It is characterized by hyperesthesia, hyperalgesia and allodynia.
Common neuropathic pain syndromes are central neuropathic pain, painful diabetic peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia, postsurgical neuropathic pain, HIV-related neuropathy, lumbosacral radiculopathy and complex regional pain syndrome.

Neuropathic Pain Drug Information

Drug Information

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Symptomatic relief of moderate to severe pain, especially associated w/ neoplastic disease, MI & surgery. ...

Indication: Control of tonic-clonic (grand mal) status epilepticus. Prevention & treatment of seizures during or follo...

Indication: Peripheral & central neuropathic pain, generalised anxiety disorder (GAD) in adults. Adjunctive therapy in...

Indication: Depression including depression w/ associated anxiety. Generalized anxiety disorder (GAD) including long-term ...

Indication: Peripheral neuropathies. Inj: Megaloblastic anaemia due to vit B12 deficiency.

Indication: Adjunctive therapy in treatment of partial seizures w/ & w/o secondary generalization in adults & chil...

Indication: Moderate to severe pain.

Indication: Moderate to severe pain.

Indication: Severe acute & chronic pain. Painful diagnostic or therapeutic measures.

1  /  8
Editor's Recommendations
Most Read Articles
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Roshini Claire Anthony, 6 days ago

Critical or severe COVID-19 disease could raise the risk of negative perinatal outcomes in pregnant women, according to an observational study from the US.

Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.